CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 30 enrolled
Drug / intervention
Glasdegib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04231851
NCT04231851Phase 2Active
CompareCT.gov

Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

University of California, Irvine·interventional·Posted Jan 18, 2020·Updated Mar 6, 2026

In Brief

A Phase 2 clinical trial evaluating Glasdegib and CPX-351 for Acute Myelogenous Leukemia (AML) Due to Therapy and Acute Myeloid Leukemia With Myelodysplasia-Related Changes. Active but no longer recruiting, targeting 30 participants across 4 sites.

Detailed Summary

This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related acute myeloid leukemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
CountriesUnited States
CollaboratorsJazz Pharmaceuticals, Pfizer

Timeline

Phase 2Active
20202021202220232024202520262027
First PostedJan 18, 2020
Enrollment StartFeb 19, 2020
Primary CompletionJun 30, 2024
Study CompletionJun 30, 2027
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 6.5 years ago

Interventions

Glasdegibdrug

Given PO

CPX-351drug

Given IV